UNSPSC 51452702: Epsiprantel

This classification denotes an antihelminthic agent with the molecular formula C20H26N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C1SPQ0FSR, chemically known as 2-(cyclohexylcarbonyl)-4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazino(2,1-a)(2)benzazepine but generally known as epsiprantel, which bears US NIH Compound Identifier 72026. European Medicines Agency schedules Epsiprantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06590MIG.

UNSPSC 51452702 Epsiprantel is a Commodity code that in practice captures state and local procurement of pharmaceutical products and related medical supplies for public health initiatives, though the recent opportunities in the source show limited direct purchasing of epsiprantel itself. State and local governments are instead using this and related pharmaceutical commodity codes to procure a broader range of drugs and health-related supplies through cooperative purchasing vehicles and competitive bidding. Issuing bodies include state health departments and county health authorities; the Illinois Department of Public Health and Seminole County, Florida appear in the recent record.

Illinois Department of Public Health awarded a pharmaceutical warehouse contract to Chartwell Rx LLC in August 2026 through the MMCAP Infuse cooperative purchasing consortium, supplying Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets for $2,999,999.11 over a three-year term including renewal options, under an Invitation for Bid process. Seminole County, Florida issued an IFB in June 2026 to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring E-Verify compliance and fixed-fee pricing. Recent activity is concentrated in Florida and Illinois; the code shows limited recent solicitation volume overall, and the opportunities posted do not demonstrate active market demand specifically for epsiprantel products.